{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:40:49Z","timestamp":1792784449435,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,9,8]],"date-time":"2020-09-08T00:00:00Z","timestamp":1599523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,9,8]],"date-time":"2020-09-08T00:00:00Z","timestamp":1599523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Universit\u251c\u00e1 degli Studi di Pavia","id":[{"id":"https:\/\/ror.org\/00s6t1f81","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s40256-020-00436-8","type":"journal-article","created":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T21:02:27Z","timestamp":1599512547000},"page":"231-240","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Meta-Analysis Comparing Potent Oral P2Y12 Inhibitors versus Clopidogrel in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3451-7484","authenticated-orcid":false,"given":"Matteo","family":"Casula","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Fortuni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Ferlini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Fabris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Oltrona Visconti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Leonardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,8]]},"reference":[{"key":"436_CR1","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1161\/CIRCULATIONAHA.113.005119","volume":"129","author":"SS Chugh","year":"2014","unstructured":"Chugh SS, Havmoeller R, Narayanan K, Singh D, Rienstra M, Benjamin EJ, et al. Worldwide epidemiology of atrial fibrillation. Circulation. 2014;129:837\u201347.","journal-title":"Circulation"},{"key":"436_CR2","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1093\/europace\/eut373","volume":"16","author":"GYH Lip","year":"2014","unstructured":"Lip GYH, Laroche C, Dan G-A, Santini M, Kalarus Z, Rasmussen LH, et al. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. Europace. 2014;16:308\u201319.","journal-title":"Europace."},{"key":"436_CR3","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","volume":"37","author":"P Kirchhof","year":"2016","unstructured":"Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893\u2013962.","journal-title":"Eur Heart J"},{"key":"436_CR4","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"L Wallentin","year":"2009","unstructured":"Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045\u201357.","journal-title":"N Engl J Med"},{"key":"436_CR5","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","volume":"357","author":"SD Wiviott","year":"2007","unstructured":"Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001\u201315.","journal-title":"N Engl J Med"},{"key":"436_CR6","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1016\/j.jacc.2013.02.036","volume":"61","author":"N Sarafoff","year":"2013","unstructured":"Sarafoff N, Martischnig A, Wealer J, Mayer K, Mehilli J, Sibbing D, et al. Triple therapy with aspirin, prasugrel, and vitamin k antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation. J Am Coll Cardiol. 2013;61:2060\u20136.","journal-title":"J Am Coll Cardiol"},{"key":"436_CR7","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","volume":"39","author":"M Valgimigli","year":"2018","unstructured":"Valgimigli M, Bueno H, Byrne RA, Collet J-P, Costa F, Jeppsson A, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur Heart J. 2018;39:213\u201360.","journal-title":"Eur Heart J"},{"key":"436_CR8","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.jtcvs.2016.07.044","volume":"152","author":"GN Levine","year":"2016","unstructured":"Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, et al. 2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease. J Thorac Cardiovasc Surg. 2016;152:1243\u201375.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"436_CR9","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"B Ibanez","year":"2018","unstructured":"Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2018;39:119\u201377.","journal-title":"Eur Heart J"},{"key":"436_CR10","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","volume":"37","author":"M Roffi","year":"2016","unstructured":"Roffi M, Patrono C, Collet J-P, Mueller C, Valgimigli M, Andreotti F, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2016;37:267\u2013315.","journal-title":"Eur Heart J"},{"key":"436_CR11","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","volume":"41","author":"J Knuuti","year":"2020","unstructured":"Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41:407\u201377.","journal-title":"Eur Heart J"},{"key":"436_CR12","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.thromres.2014.10.016","volume":"135","author":"O\u00d6 Braun","year":"2015","unstructured":"Braun O\u00d6, Bico B, Chaudhry U, Wagner H, Koul S, Tyd\u00e9n P, et al. Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome. Thromb Res. 2015;135:26\u201330.","journal-title":"Thromb Res"},{"issue":"25","key":"436_CR13","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","volume":"375","author":"CM Gibson","year":"2016","unstructured":"Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med. 2016;375(25):2423\u201334.","journal-title":"N Engl J Med"},{"key":"436_CR14","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","volume":"377","author":"CP Cannon","year":"2017","unstructured":"Cannon CP, Bhatt DL, Oldgren J, Lip GYH, Ellis SG, Kimura T, et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med. 2017;377:1513\u201324.","journal-title":"N Engl J Med"},{"key":"436_CR15","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.","journal-title":"PLoS Med."},{"key":"436_CR16","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/2046-4053-2-81","volume":"2","author":"MW Langendam","year":"2013","unstructured":"Langendam MW, Akl EA, Dahm P, Glasziou P, Guyatt G, Sch\u00fcnemann HJ. Assessing and presenting summaries of evidence in Cochrane Reviews. Syst Rev. 2013;2:81.","journal-title":"Syst Rev."},{"key":"436_CR17","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","volume":"380","author":"RD Lopes","year":"2019","unstructured":"Lopes RD, Heizer G, Aronson R, Vora AN, Massaro T, Mehran R, et al. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med. 2019;380:1509\u201324.","journal-title":"N Engl J Med"},{"key":"436_CR18","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/S0140-6736(19)31872-0","volume":"394","author":"P Vranckx","year":"2019","unstructured":"Vranckx P, Valgimigli M, Eckardt L, Tijssen J, Lewalter T, Gargiulo G, et al. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet. 2019;394:1335\u201343.","journal-title":"Lancet"},{"key":"436_CR19","volume-title":"XARELTO (Rivaroxaban): prescribing information","author":"US Fda","year":"2017","unstructured":"Fda US. XARELTO (Rivaroxaban): prescribing information. White Oak: US FDA; 2017."},{"key":"436_CR20","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.ijcard.2016.11.160","volume":"228","author":"Y Xin","year":"2017","unstructured":"Xin Y, Zhang H, Li Y, Guan Q, Guo L, Gao Y, et al. Efficacy and safety of ticagrelor versus clopidogrel with different dosage in high-risk patients with acute coronary syndrome. Int J Cardiol. 2017;228:275\u20139.","journal-title":"Int J Cardiol"},{"issue":"4","key":"436_CR21","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.3390\/jcm9041120","volume":"9","author":"C Eyileten","year":"2020","unstructured":"Eyileten C, Postula M, Jakubik D, Toma A, Mirowska-Guzel D, Patti G, et al. Non-vitamin K oral anticoagulants (NOAC) versus vitamin K antagonists (VKA) for atrial fibrillation with elective or urgent percutaneous coronary intervention: a meta-analysis with a particular focus on combination type. J Clin Med. 2020;9(4):1120. https:\/\/doi.org\/10.3390\/jcm9041120.","journal-title":"J Clin Med."},{"issue":"12","key":"436_CR22","doi-asserted-by":"publisher","first-page":"CD013252","DOI":"10.1002\/14651858.cd013252.pub2","volume":"12","author":"S Al Said","year":"2019","unstructured":"Al Said S, Alabed S, Kaier K, Tan AR, Bode C, Meerpohl JJ, et al. Non-vitamin K antagonist oral anticoagulants (NOACs) post-percutaneous coronary intervention: a network meta-analysis. Cochrane Database Syst Rev. 2019;12(12):CD013252. https:\/\/doi.org\/10.1002\/14651858.cd013252.pub2.","journal-title":"Cochrane Database Syst Rev."},{"issue":"46","key":"436_CR23","doi-asserted-by":"publisher","first-page":"3757","DOI":"10.1093\/eurheartj\/ehz732","volume":"40","author":"G Gargiulo","year":"2019","unstructured":"Gargiulo G, Goette A, Tijssen J, Eckardt L, Lewalter T, Vranckx P, et al. Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomiz. Eur Heart J. 2019;40(46):3757\u201367. https:\/\/doi.org\/10.1093\/eurheartj\/ehz732.","journal-title":"Eur Heart J."},{"key":"436_CR24","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1161\/CIRCULATIONAHA.119.044584","volume":"141","author":"RD Lopes","year":"2020","unstructured":"Lopes RD, Leonardi S, Wojdyla DM, Vora AN, Thomas L, Storey RF, et al. Stent thrombosis in patients with atrial fibrillation undergoing coronary stenting in the AUGUSTUS trial. Circulation. 2020;141:781\u20133.","journal-title":"Circulation"},{"key":"436_CR25","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1016\/j.jacc.2016.07.760","volume":"68","author":"G Giustino","year":"2016","unstructured":"Giustino G, Chieffo A, Palmerini T, Valgimigli M, Feres F, Abizaid A, et al. Efficacy and safety of dual antiplatelet therapy after complex PCI. J Am Coll Cardiol. 2016;68:1851\u201364.","journal-title":"J Am Coll Cardiol"},{"key":"436_CR26","doi-asserted-by":"publisher","first-page":"580","DOI":"10.2459\/JCM.0000000000000533","volume":"18","author":"L De Luca","year":"2017","unstructured":"De Luca L, Musumeci G, Leonardi S, Gonzini L, Cavallini C, Calabr\u00f2 P, et al. Antithrombotic strategies in the catheterization laboratory for patients with acute coronary syndromes undergoing percutaneous coronary interventions. J Cardiovasc Med. 2017;18:580\u20139.","journal-title":"J Cardiovasc Med."},{"key":"436_CR27","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ijcard.2018.08.019","volume":"273","author":"F Fortuni","year":"2018","unstructured":"Fortuni F, Ferlini M, Leonardi S, Angelini F, Crimi G, Somaschini A, et al. Dual versus triple therapy in patients on oral anticoagulants and undergoing coronary stent implantation: a systematic review and meta-analysis. Int J Cardiol. 2018;273:80\u20137.","journal-title":"Int J Cardiol"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-020-00436-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-020-00436-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-020-00436-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,7]],"date-time":"2021-09-07T19:22:30Z","timestamp":1631042550000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-020-00436-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,8]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["436"],"URL":"https:\/\/doi.org\/10.1007\/s40256-020-00436-8","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,8]]},"assertion":[{"value":"8 September 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was used in the preparation of this manuscript. Open access funding provided by Universit\u00c3 degli Studi di Pavia within the CRUI-CARE Agreement.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Matteo Casula, Federico Fortuni, Marco Ferlini, Francesca Fabris, Luigi Oltrona Visconti and Sergio Leonardi declare they have no potential conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"The publication of this paper has been approved by all co-authors, as well as by the responsible authorities, tacitly or explicitly, at the institute where the work has been carried out.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Data will be made available by contacting the corresponding author.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"MC conceived the idea for this work, designed the protocol, conducted the search and study selection processes, collected and analyzed the data, drafted this manuscript, and decided to submit it for publication. FF conducted the search and study selection processes, assessed the data extracted for completeness and accuracy, reviewed the statistical analysis, and critically revised the manuscript. All authors critically analyzed the data, revised the manuscript with important intellectual contributions, and approved its final version prior to submission.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}